Cargando…
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses via MEK-ERK Signaling
N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an endogenous immunomodulatory peptide that is generated from thymosin β4 (Tβ4) through stepwise hydrolysis, involving meprin-α and prolyl endopeptidase (PREP). It is well acknowledged that AcSDKP exerts beneficial effects on multiple cardiovascular...
Autores principales: | Shi, Yingying, Zhou, Mingxia, Yan, Junkai, Gong, Zizhen, Wu, Jin, Chen, Yuanwen, Chen, Yingwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218092/ https://www.ncbi.nlm.nih.gov/pubmed/32435194 http://dx.doi.org/10.3389/fphar.2020.00593 |
Ejemplares similares
-
N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition
por: Nagai, Takako, et al.
Publicado: (2014) -
βklotho is essential for the anti‐endothelial mesenchymal transition effects of N‐acetyl‐seryl‐aspartyl‐lysyl‐proline
por: Gao, Rongfen, et al.
Publicado: (2019) -
N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
por: Kanasaki, Keizo, et al.
Publicado: (2014) -
N-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice
por: Chan, Gary C. W., et al.
Publicado: (2015) -
Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis
por: Srivastava, Swayam Prakash, et al.
Publicado: (2016)